Search the Newsreel

Kenvue Earnings: Rare Volume Growth Despite Muted US and Europe Performance Impresses

Kenvue reported 3% revenue growth and 7% adjusted EPS growth in the second quarter, driven by 0.7% volume growth despite muted performance in the US and Europe. This volume growth was a rare achievement for the company. Morningstar highlighted this positive performance in their …

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Corvus Pharmaceuticals reported its second-quarter 2026 financial results, highlighting that its cash, cash equivalents, and marketable securities reached $215.2 million, providing a runway into Q2 2028. The company is actively enrolling patients in Phase 3 trials for soquelitinib in relapsed/refractory peripheral T-cell lymphoma (PTCL) …

Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cenovus Energy (TSE:CVE) Shares Cross Above 200-Day Moving Average - Time to Sell?

Cenovus Energy (TSE:CVE) shares recently crossed above their 200-day moving average, signaling improved technical momentum. The company reported strong quarterly earnings and increased its dividend, yet insiders have sold a significant number of shares. Analysts maintain a bullish outlook with an average "Buy" rating …

Vulcan Materials Co. stock outperforms competitors despite losses on the day

Shares of Vulcan Materials Co. (VMC) fell 1.79% to $281.63, breaking a three-day winning streak, on a day when the broader market also saw losses. Despite this decline, the stock still outperformed the S&P 500 Index and the Dow Jones Industrial Average. The article …

Kenvue Inc. (KVUE) Stock Forecasts

Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, having spun off from Johnson & Johnson in May 2023. Recent earnings show rare volume growth despite muted performance in the US and Europe. Analysts continue to evaluate its market position and financial …

Alivus Life Sciences Q1 Results: Net profit rises to ₹160 crore

Kenvue (NYSE:KVUE) Posts Earnings Results, Misses Expectations By $0.01 EPS

Kenvue (NYSE:KVUE) reported its quarterly earnings, missing analyst expectations by $0.01 EPS with $0.31 per share, against an estimated $0.32. The company's revenue of $3.96 billion also slightly missed the $3.97 billion forecast but marked a 3.0% increase year-over-year. Kenvue declared a quarterly dividend …

Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary

Corvus Pharmaceuticals reported a wider net loss of $(17.96)M and diluted EPS of $(0.19) for Q2 2026, compared to the year-ago quarter, as the company continues to invest heavily in clinical development. Despite the increased losses and no product revenue, Corvus Pharmaceuticals is progressing …

Press Release: Kenvue Reports Second Quarter 2026 Results

This document is a press release from Kenvue reporting their second quarter 2026 financial results. Without further content, the specific details of these results are unknown.

Cenovus Energy (TSX:CVE) Lifts Guidance Following Strong Results With Valuation Back In Focus

Cenovus Energy recently reported strong second-quarter 2026 results, showing higher sales, net income, and upstream production, alongside updated guidance and capital returns through dividends and share buybacks. Despite a significant year-to-date share price increase of 64.70% and a five-year return of 326.13%, the company …

Corvus Eczema Trial Is Expected to Enroll About 200 Patients

Corvus Pharmaceuticals reported a Q2 2026 net loss of $18.0 million, an increase from $8.0 million a year prior, primarily due to higher clinical trial and personnel costs for soquelitinib. The company maintains a strong cash position of $215.2 million, expected to fund operations …

Kenvue Inc. stock falls Thursday, underperforms market

Kenvue Inc. (KVUE) stock fell by 2.49% on Thursday, closing at $19.18, and underperformed the broader market. This decline occurred during an overall poor trading session where the S&P 500 Index dropped 0.18% and the Dow Jones Industrial Average fell 0.85%. The stock's fall …

Kenvue Stock Falls 2.7% as Growth Arrives With Thinner Margins

This article first appeared on GuruFocus. Kenvue (NYSE:KVUE), the consumer-health giant behind Tylenol, Neutrogena and Listerine, delivered another quarter of steady growth, but that was not enough to keep investors happy as the stock slid about 2.7% on Thursday. Revenue climbed 3% year over …

Corvus Pharmaceuticals earnings up next as trial progress eyed

Corvus Pharmaceuticals is set to release its second-quarter earnings, with investors focused on clinical trial progress for its lead drug candidate, soquelitinib, and its cash burn rate. The pre-revenue biotech is expected to post a loss of 15 cents per share, with current cash …

KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise

Kenvue Inc. (KVUE) reported its Q2 2026 results, with both adjusted earnings and net sales missing Zacks Consensus Estimates despite showing increases year-over-year. The company experienced narrowing margins due to inflation and foreign exchange, while its Self Care segment returned to organic growth and …

Kenvue second quarter results fall short of expectations, sending shares lower

Kenvue Inc. (NYSE:KVUE) reported second-quarter results that fell slightly below Wall Street expectations, causing its shares to drop by about 2%. The consumer health company reported adjusted diluted earnings per share of $0.31 on revenue of $3.96 billion, missing analyst estimates of $0.32 EPS …

Corvus Pharmaceuticals Q2 Earnings Call Highlights

Corvus Pharmaceuticals reported a wider Q2 loss due to increased R&D spending on soquelitinib trials, but its substantial cash position is expected to fund operations into Q2 2028. The company provided updates on its clinical programs, including the Phase III PTCL trial with an …

Market movers: Western Digital, Sandisk, Kenvue, Fiserv...

Fiserv, Kenvue, Western Digital, and Sandisk experienced declines due to lowered outlooks or missed expectations. Fiserv's shares fell over 3% after reducing its 2026 organic revenue forecast, while Kenvue's shares dropped 2% after missing Q2 earnings estimates. Western Digital and Sandisk both saw their …

Cenovus Energy Inc. stock rises Thursday, outperforms market

Cenovus Energy Inc. (CVE) saw its stock rally by 2.04% to C$39.61 on Thursday, outperforming the broader Canadian market. The S&P/TSX Composite Index fell by 0.03%, while Cenovus Energy Inc. closed 10.2% below its 52-week high.

FMR LLC discloses 8.2% Kenvue Inc. (KVUE) ownership in amended 13G filing

FMR LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 8.2% in Kenvue Inc. (KVUE), amounting to 157,051,418.71 shares of common stock. The filing details FMR LLC's sole voting power over 107,583,737.47 shares and sole dispositive power over the full 157,051,418.71 …

Kenvue stock falls after earnings miss analyst estimates

Kenvue Inc. shares dropped in premarket trading after the company reported second-quarter results that missed Wall Street's earnings and revenue estimates. Despite the miss, Kenvue saw its third consecutive quarter of net and organic sales growth, with gains across all segments and regions, and …

Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Aug 6 (Reuters) - Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, ‌tariffs and currency-related costs squeezed margins. The consumer-health ‌company, currently in the midst of a $40 billion buyout by Kimberly-Clark, ​expects the deal to close in the …

Kenvue incumple las previsiones trimestrales por la presión de la inflación y los aranceles sobre sus márgenes

Kenvue Posts Higher Profit, Sales as Turnaround Continues

Kenvue reported higher profit and sales in the second quarter, with net sales increasing 3% to $3.96 billion, slightly below Wall Street estimates. The company, known for products like Tylenol and Listerine, achieved a profit of $456 million, or 24 cents a share, up …

Earnings Flash (KVUE) Kenvue Inc. Posts Q2 Adjusted EPS $0.31 per Share, vs. FactSet Est of $0.32

Kenvue Inc. (KVUE) reported its Q2 adjusted earnings per share (EPS) of $0.31, which fell short of FactSet's estimate of $0.32. This financial update indicates that the company's Q2 performance did not meet analyst expectations for its adjusted EPS. The article is part of …

Kenvue Inc. 1Q 2026: Revenue $3.96B, EPS $0.24— 10-Q Summary

Kenvue Inc. reported strong first-quarter 2026 results, with revenue of $3.96 billion and diluted EPS of $0.24, exceeding prior-year figures. Growth was primarily driven by e-commerce strength and significant gains in its Skin Health & Beauty segment. The company also highlighted ongoing operational initiatives, …

Earnings Flash (KVUE) Kenvue Inc. Reports Q2 Revenue $3.96B, vs. FactSet Est of $3.97B

Kenvue Inc. (KVUE) reported its Q2 revenue at $3.96 billion, falling slightly short of FactSet's estimate of $3.97 billion. This announcement follows earlier news that Kenvue missed quarterly estimates due to inflation and tariffs squeezing margins, and also reported Q2 adjusted EPS of $0.31 …

Kenvue Inc. (KVUE) Q2 2026 Earnings

Kenvue Inc. (KVUE) reported its Q2 2026 earnings, missing analyst expectations for both EPS ($0.31 vs $0.32 est) and revenue ($3.96B vs $3.97B est). This marks the end of a four-quarter beat streak, with adjusted gross margin narrowing due to inflation, tariffs, and currency …

Form 8K Kenvue Inc For: 6 August By Investing.com

This article reports that Kenvue Inc. has filed a Form 8K on August 6th. The brief mention indicates a significant event or disclosure made by the company to the SEC. The content itself is very minimal, serving primarily as an announcement of the filing.

Kenvue Reports Second Quarter 2026 Results

Delivered Third Consecutive Quarter of Net and Organic Sales1 Growth Net Sales Increased 3.0%; Organic SalesIncreased 1.6% Diluted EPS Increased 9% to $0.24; Adjusted Diluted EPS1 Increased 7% to $0.31 Results Met or Exceeded the Company's Plans Across Key Metrics SUMMIT, N.J., August 06, …

Kenvue Inc. (NYSE: KVUE) grows Q2 sales 3% and lifts EPS 9%

Kenvue Inc. reported Q2 2026 financial results, showing a 3.0% increase in net sales to $3.96 billion and a 9% rise in diluted earnings per share to $0.24. The company highlighted strong organic sales growth, particularly in Skin Health and Beauty, and announced U.S. …

Kenvue posts Q2 2026: Net sales +3.0%, diluted EPS $0.24, adjusted EPS $0.31

Kenvue (KVUE) reported its Q2 2026 financial results, showing net sales of $3.955 billion, a 3.0% increase year-over-year, and diluted earnings per share of $0.24, with adjusted diluted EPS at $0.31. The company achieved three consecutive quarters of net and organic sales growth across …

Alivus Life Sciences fixes Sep 1 record date for ₹5 dividend

Price to earnings forward of KVUTZAT ACRO LTD – TASE:ACRO

Kenvue (KVUE) Lags Q2 Earnings and Revenue Estimates

Kenvue (KVUE) reported Q2 earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.32, though it represents an increase from $0.29 per share a year ago. The company also missed revenue estimates, posting $3.96 billion against an expected $3.99 billion. Despite these …